TRPV1 Receptor and Cannabinoids
How cannabis compounds interact with the 'capsaicin receptor' — a foundational target outside the classical CB1/CB2 system.
TRPV1 isn't a terpene — it's an ion channel, and one of the most studied non-CB targets for cannabinoids. The science here is real but mostly preclinical: cell cultures, rodents, isolated tissues. Claims that 'CBD works through TRPV1 in humans' are extrapolations, not proven clinical mechanisms. Treat TRPV1 as a plausible piece of the puzzle for pain, inflammation, and temperature sensation — not a settled explanation for what you feel after a dose.
What TRPV1 is
TRPV1 (Transient Receptor Potential Vanilloid type 1) is a non-selective cation channel expressed on the membranes of many cell types, most famously on small-diameter sensory neurons that carry pain and temperature signals [1]. It was cloned in 1997 by the Julius lab as the receptor activated by capsaicin, the pungent compound in chili peppers [1]. Activation opens the channel to calcium and sodium, depolarizing the neuron and producing the burning sensation associated with hot peppers, noxious heat (>43°C), and acidic conditions. Strong evidence
David Julius later shared the 2021 Nobel Prize in Physiology or Medicine in part for this discovery [2]. TRPV1 is now understood as a polymodal sensor — it integrates heat, protons, lipids, and a long list of endogenous and exogenous ligands. Paradoxically, sustained or high-dose activation leads to desensitization, which is the basis for capsaicin's use as a topical analgesic.
Where TRPV1 is expressed
TRPV1 is enriched in primary afferent sensory neurons of the dorsal root and trigeminal ganglia [1][3]. It is also detectable in keratinocytes, urothelium of the bladder, enteric neurons of the gut, vascular endothelium, and several brain regions including the hippocampus, hypothalamus, and periaqueductal gray [3]. Strong evidence
This broad distribution is why TRPV1 ligands have been investigated for conditions ranging from neuropathic pain and overactive bladder to itch, cough, and anxiety. It also means selectivity is a real problem for drug development: a systemic TRPV1 antagonist can cause hyperthermia by blocking the channel's role in thermoregulation, an effect that derailed several clinical programs [4].
Cannabinoid interactions with TRPV1
The endocannabinoid anandamide (AEA) was one of the first lipids shown to directly activate TRPV1, binding at an intracellular site [5]. This made TRPV1 a de facto 'third' endocannabinoid-system receptor alongside CB1 and CB2, although the pharmacology is messier than that framing suggests. Strong evidence
Phytocannabinoids documented to activate or modulate TRPV1 in vitro include cannabidiol (CBD), cannabidivarin (CBDV), cannabigerol (CBG), cannabinol (CBN), Δ9-tetrahydrocannabivarin (THCV), and cannabichromene (CBC) [6]. Most act as agonists at micromolar concentrations and, like capsaicin, can desensitize the channel with sustained exposure. This desensitization is the most commonly proposed mechanism for CBD's reported anti-inflammatory and anti-hyperalgesic effects in preclinical models [6][7]. [evidence:weak in humans]
Importantly, the concentrations needed to engage TRPV1 in cell assays (often 1–10 μM) are higher than typical plasma levels reached with oral CBD dosing in humans. Whether TRPV1 is meaningfully recruited at clinically relevant exposures — versus other targets like GPR55, 5-HT1A, or adenosine reuptake — is unresolved [7]. Disputed
What the human evidence actually shows
Almost all of the TRPV1-cannabinoid literature is preclinical: HEK293 cells expressing recombinant TRPV1, isolated dorsal root ganglion neurons, or rodent models of inflammation, neuropathy, and seizure [6][7]. These studies are mechanistically informative but do not by themselves prove that TRPV1 mediates any specific effect of cannabis in people. [evidence:strong for preclinical, none for direct human confirmation]
The one cannabinoid medicine with robust human efficacy — purified CBD (Epidiolex) in Dravet and Lennox-Gastaut syndromes — has its anticonvulsant effect attributed primarily to GPR55 antagonism and inhibition of equilibrative nucleoside transporter 1, with TRPV1 considered a secondary possibility [8]. No cannabinoid-based drug has been approved on a TRPV1 mechanism, and no controlled human trial has cleanly isolated TRPV1 as the site of action for a cannabis effect.
In short: TRPV1 is a real and well-characterized target for cannabinoids in the lab. Translating that into 'cannabis works because of TRPV1' is, at present, a hypothesis.
Terpenes and TRPV1
Several terpenes found in cannabis have been reported to interact with TRP channels, though TRPV1 specifically is hit less often than TRPA1 or TRPM8. Camphor activates TRPV1 at high concentrations and also desensitizes it [9]. Eucalyptol (1,8-cineole) and some monoterpenes show weak TRPV1 activity in heterologous expression systems [9]. Weak / limited
The popular claim that the cannabis entourage effect is driven by terpene action at TRPV1 is largely speculative. Terpene concentrations in inhaled or ingested cannabis are typically far below those used in in vitro TRP assays, and direct human pharmacology is sparse. Treat 'terpene X hits TRPV1' claims as biochemically plausible but clinically unproven. [evidence:none for clinical relevance]
Related targets and further reading
TRPV1 is one of six TRPV channels and sits within a larger TRP superfamily relevant to cannabinoid pharmacology. CBD and several other phytocannabinoids also modulate TRPA1 (the 'wasabi receptor'), TRPV2, TRPV3, TRPV4, and TRPM8 [6]. For the classical receptors, see CB1 receptor and CB2 receptor. For the endogenous ligand most relevant to TRPV1, see Anandamide.
Sources
- Peer-reviewed Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature, 389(6653), 816–824.
- Government The Nobel Assembly at Karolinska Institutet (2021). Press release: The Nobel Prize in Physiology or Medicine 2021 — David Julius and Ardem Patapoutian. ↗
- Peer-reviewed Cavanaugh, D. J., Chesler, A. T., Jackson, A. C., Sigal, Y. M., Yamanaka, H., Grant, R., O'Donnell, D., Nicoll, R. A., Shah, N. M., Julius, D., & Basbaum, A. I. (2011). Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. Journal of Neuroscience, 31(13), 5067–5077.
- Peer-reviewed Gavva, N. R., et al. (2008). Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain, 136(1–2), 202–210.
- Peer-reviewed Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400(6743), 452–457.
- Peer-reviewed Muller, C., Morales, P., & Reggio, P. H. (2019). Cannabinoid ligands targeting TRP channels. Frontiers in Molecular Neuroscience, 11, 487.
- Peer-reviewed Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134(4), 845–852.
- Peer-reviewed Gray, R. A., & Whalley, B. J. (2020). The proposed mechanisms of action of CBD in epilepsy. Epileptic Disorders, 22(S1), S10–S15.
- Peer-reviewed Vriens, J., Nilius, B., & Voets, T. (2014). Peripheral thermosensation in mammals. Nature Reviews Neuroscience, 15(9), 573–589.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.